Table 1.
Patient demographics and treatment characteristics.
| Variable | Total sample (N = 150) | First brain metastatic event (N = 77) | Second brain metastatic event (N = 73) | p-Value* |
|---|---|---|---|---|
| Karnofsky Performance Status [N (%)] | 0.0191 | |||
| 90–100 | 28 (18.7) | 18 (23.4) | 10 (13.7) | |
| 70–80 | 78 (52.0) | 44 (57.1) | 34 (46.6) | |
| <70 | 44 (29.3) | 15 (19.5) | 29 (39.7) | |
| Recursive Partitioning Analysis [N (%)] | 0.0002 | |||
| 1 | 26 (17.3) | 8 (10.4) | 18 (24.7) | |
| 2 | 81 (54.0) | 54 (70.1) | 27 (36.9) | |
| 3 | 43 (28.7) | 15 (19.5) | 28 (38.4) | |
| Primary location [N (%)] | 0.0141 | |||
| Lung | 83 (55.3) | 41 (53.2) | 42 (57.5) | |
| Breast | 20 (13.3) | 9 (11.7) | 11 (15.1) | |
| Melanoma | 13 (8.7) | 12 (15.6) | 1 (1.4) | |
| Other | 34 (22.7) | 15 (19.5) | 19 (26.0) | |
| Gender [N (%)] | 0.0035 | |||
| Male | 76 (50.7) | 30 (39.0) | 46 (63.0) | |
| Female | 74 (49.3) | 47 (61.0) | 27 (37.0) | |
| Age [Mean (SD)] | 61.3 (13.4) | 63.6 (14.0) | 58.8 (12.4) | 0.0274 |
| Age [N (%)] | 0.0133 | |||
| ≤65 | 87 (58.0) | 37 (48.1) | 50 (68.5) | |
| >65 | 63 (42.0) | 40 (52.0) | 23 (31.5) | |
| Initial metastases [N (%)] | 0.2496 | |||
| Brain | 87 (58.0) | 41 (53.2) | 46 (63.0) | |
| Other | 63 (42.0) | 36 (46.8) | 27 (37.0) | |
| Number of metastases [N (%)] | 0.4805 | |||
| 1 or 2 | 105 (70.0) | 56 (72.7) | 49 (67.1) | |
| 3 or more | 45 (30.0) | 21 (27.3) | 24 (32.9) | |
| Extracranial metastases [N (%)] | 0.8718 | |||
| Present | 77 (51.3) | 39 (50.6) | 38 (52.1) | |
| Absent | 73 (48.7) | 38 (49.4) | 35 (47.9) |
*p-Value based on two-sample T-test for continuous variable (age) and Fisher’s exact tests for categorical variables.